March 24, 2026-
Ocugen, Inc. (NASDAQ: OCGN) has announced encouraging 12-month Phase 2 clinical trial results for OCU410 (AAV5-RORA), its investigational AAV-based gene therapy designed to treat geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD). The data from the ArMaDa Phase 2 trial demonstrated a statistically significant 31% reduction in lesion growth at the optimal dose compared with the control group, supporting further development as the company prepares for a Phase 3 study.
Dry age-related macular degeneration affects approximately 266 million people globally, with geographic atrophy representing an advanced stage of the disease that leads to progressive degeneration of retinal cells and irreversible central vision loss. In the United States and Europe alone, GA impacts an estimated 2–3 million individuals, and the prevalence is expected to increase as global populations age. Current treatments in the U.S. target the complement pathway and require frequent intravitreal injections—often 6 to 12 per year indefinitely, placing a significant burden on patients.
OCU410 is designed as a one-time AAV5-mediated gene therapy delivered via subretinal injection, introducing the RORA gene (retinoid-related orphan receptor alpha) into retinal cells. RORA plays a regulatory role in several biological pathways involved in retinal health, including oxidative stress response, inflammation, complement regulation, lipid metabolism, and drusen formation. By targeting multiple disease pathways simultaneously, the therapy aims to protect photoreceptors and slow the progression of retinal degeneration.
Results from the Phase 2 ArMaDa trial showed that patients receiving the medium (optimal) dose of OCU410 experienced a 31% reduction in GA lesion growth compared with untreated controls at 12 months, a statistically significant improvement. Additional analyses demonstrated a 27% slower rate of ellipsoid zone loss, a key biomarker indicating preservation of photoreceptor structure and function. Notably, 55% of treated patients experienced at least a 30% reduction in lesion growth, suggesting meaningful biological activity.
Subgroup analysis further supported these findings. Among patients with baseline lesion sizes between 5 mm² and 17.5 mm², treatment with the medium dose resulted in a 33% reduction in lesion growth, with similar effects observed in the higher dose cohort. These results compare favorably with currently approved GA therapies, which have reported lesion growth reductions of approximately 15% at 12 months and 22% at 24 months, suggesting the potential for a stronger therapeutic effect.
Safety findings were also encouraging. The trial builds on the favorable safety profile observed in Phase 1, with no OCU410-related serious adverse events reported and no cases of endophthalmitis, retinal detachment, vasculitis, choroidal neovascularization, or ischemic optic neuropathy observed to date.
The Phase 2 study enrolled 51 patients aged 50 years or older with GA lesions located in either the foveal or non-foveal region. Participants were randomized to receive a single subretinal injection of OCU410 at either 1×10¹⁰ or 3×10¹⁰ vector genomes per eye, or to remain in the untreated control group. The primary endpoint evaluated changes in lesion size using fundus autofluorescence imaging, an FDA-accepted structural endpoint used in recent GA registration studies.
Based on the strength of the data, Ocugen plans to initiate a Phase 3 registrational trial in the third quarter of 2026, enrolling up to 300 patients in an adaptive study design powered at more than 95%. The company aims to advance the program toward potential regulatory filings as part of its broader strategy to bring innovative gene therapies for blindness diseases to patients worldwide.
If successful, OCU410 could represent a durable AAV gene therapy solution for geographic atrophy, offering a one-time treatment alternative to chronic injections while addressing multiple biological pathways driving retinal degeneration.
